Replies to post #89689 on Biotech Values

[genisi]

UTHR/Tadalafil (Adcirca ) patents:

[Adcirca] orphan drug exclusivity in PAH, which can’t be overturned by a P-IV challenge, runs until Apr 2016.

Correct, plus it should get 6-month pediatric extension.

Knocking out the Adcirca CoM patent, which expires in Nov 2017, won’t provide much economic benefit to the P-IV challenger.

I tend to think the challenger is attacking the other 2 patents, which are not as strong as the CoM and run until 2020.

[rkrw]

But they'd get the 6 month exclusivity for being first to file. ROI would still be large even if brief.